31022-10-3

Basic information

• Product Name: N-alpha-Benzyl-L-alanine methyl ester
• Synonyms: N-alpha-Benzyl-L-alanine methyl ester;(S)-methyl 2-(benzylamino)propanoate;Methyl N-benzyl-L-alaninate;N-Benzyl-L-alanine methyl ester;-Methyl 2-(benzylamino)
• CAS NO: 31022-10-3
• Molecular Formula: C₁₁H₁₅NO₂
• Molecular Weight: 193.2423
• Mol File: 31022-10-3.mol

Chemical Properties

• Boiling Point: 271℃
• Flash Point: 118℃
• Appearance: /
• Density: 1.047
• Vapor Pressure: 0.007mmHg at 25°C
• Refractive Index: 1.509
• Storage Temp.: 2-8°C
• CAS DataBase Reference: N-alpha-Benzyl-L-alanine methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-alpha-Benzyl-L-alanine methyl ester(31022-10-3)
• EPA Substance Registry System: N-alpha-Benzyl-L-alanine methyl ester(31022-10-3)

Safety Data

• Hazardous Substances Data: 31022-10-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-alpha-Benzyl-L-alanine methyl ester is used as a building block for the synthesis of various pharmaceutical drugs due to its unique structure and reactivity. It serves as a precursor in the production of peptides and inhibitors, contributing to the development of new therapeutic agents.
Used in Research and Development:
N-alpha-Benzyl-L-alanine methyl ester is used as a research compound for the exploration and development of new drugs and biologically active compounds. Its unique chemical properties make it a valuable tool in medicinal chemistry for designing and testing novel pharmaceutical agents.

InChI:InChI=1/C11H15NO2/c1-9(11(13)14-2)12-8-10-6-4-3-5-7-10/h3-7,9,12H,8H2,1-2H3/t9-/m0/s1

Upstream product

• 10065-72-2 L-Alanine methyl ester 
• 100-52-7 benzaldehyde 
• 100-39-0 benzyl bromide 
• 600-22-6 pyruvic acid methyl ester 
• 100-46-9 benzylamine 
• 121441-04-1 (S)-2-Benzylamino-propionic acid; hydrochloride 
• 121441-01-8 Methyl N-(trifluoroacetyl)-N-benzylalaninate 
• 67-56-1 methanol 
• 167823-32-7 1,2:5,6-di-O-isopropylidene-α-D-glucofuranos-3-O-yl α-bromopropionate 
• 395649-41-9 methyl (E)-2-(benzylideneamino)propanoate 
• 176018-06-7 (4S,5R)-1-((R)-2-Benzylamino-propionyl)-3,4-dimethyl-5-phenyl-imidazolidin-2-one 
• 175844-92-5 (4S,5R)-1-((S)-2-Benzylamino-propionyl)-3,4-dimethyl-5-phenyl-imidazolidin-2-one 
• 2491-20-5 L-alanine methyl ester hydrochloride 
• 53933-42-9 2-(benzylidene-amino)-propionic acid methyl ester 

Downstream Products

• 141214-28-0 (S)-2-(Benzoyl-benzyl-amino)-propionic acid methyl ester 
• 573701-30-1 (2S)-2-[benzyl(methyl)amino]propan-1-ol 
• 1403983-85-6 2-[benzyl(methyl)amino]-1,1-dimethylpropan-1-ol 
• 112116-48-0 2-[benzyl(methyl)amino]-1,1-diphenylpropan-1-ol 
• 175853-53-9 methyl (2S)-2-[benzyl(methyl)amino]propanoate 
• 260254-80-6 trans-2R,5S-dimethyl-4-benzyl-piperazine 
• 911675-82-6 NH₂-(Bn)Ala-OMe hydrochloride salt 
• 141214-39-3 N-Benzyl-N-((S)-2-hydroxy-1-methyl-ethyl)-benzamide 
• 214632-86-7 (Z)-(4S,8S)-8-Benzylamino-non-6-en-4-ol 

Relevant articles and documents

Diastereoselective intramolecular allyl transfer from allyl carbamate accompanied by 5-endo-trig ring closure

To All(oc) involved: A palladium-catalyzed formal 5-endo-trig heteroannulation of enones generated in situ from amino acid derived β-keto nitriles has been realized (see scheme; Alloc=allyl carbamate). The reaction proceeds with allyl-group transfer from the carbamate protecting group to generate two new contiguous stereocenters, including one quaternary center, with high selectivity. Copyright

TETRACYCLIC HETEROARYL COMPOUNDS

The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Chiral-pool synthesis of 1,2,4-trisubstituted 1,4-diazepanes as novel σ1 receptor ligands

Starting from enantiomerically pure amino acids, 1,4-diazepanes with various substituents in 1, 2, and 4-position were synthesized following the late stage diversification strategy. The key step in the formation of the seven-membered ring was the intramolecular EDC coupling of amino acids 15, 26, and 39. The configuration in 2-position does not influence the σ1 affinity and selectivity over related receptors. A cyclohexylmethyl or a butyl group are the preferred substituents in 4-position, whereas a methyl moiety in 2-position and a (substituted) benzyl moiety in 1-position result in the highest σ1 affinity. These results fit nicely to the reported σ1 pharmacophore models. The compounds did not inhibit the structurally related fungal enzyme sterol Δ8,7-isomerase, but showed inhibition of diverse enzymes in late cholesterol biosynthesis at high concentrations. In a screening against more than 50 target proteins, (2S)-1-benzyl-4-(4-methoxybenzyl)-2-methyl-1,4-diazepane ((S)-28b, Ki(σ1) = 0.86 nM) showed a clean receptor profile. The dose dependent potentiation of electrically stimulated contractions of guinea pig vas deferens indicates σ1 agonistic activity of (S)-28b. Even at a dose of 100 mg/kg (S)-28b did not induce severe toxic or behavioral effects in the Irwin screen. Clear cognition enhancing effects were observed for (S)-28b after inducing amnesia by scopolamine.

THERAPEUTIC COMPOUNDS

The present invention relates to compounds that are antagonists of the orexin-1 receptor. The compounds have the structural formula (I) defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with orexin-1 receptor activity.

Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof

The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds present in, e.g., coffee. Also, the invention relates to the discovery of specific compounds and compositions containing that function as bitter taste blockers and the use thereof as bitter taste blockers or flavor modulators in, e.g., coffee and coffee flavored foods, beverages and medicaments. Also, the present invention relates to the discovery of a compound that antagonizes numerous different human T2Rs and the use thereof in assays and as a bitter taste blocker in compositions for ingestion by humans and animals.

BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF

The present invention includes compounds and compositions known to modify the perception of bitter taste, and combinations of said compositions and compounds with additional compositions, compounds, and products. Exemplary compositions comprise one or more of the following: cooling agents; inactive drug ingredients; active pharmaceutical ingredients; food additives or foodstuffs; flavorants, or flavor enhancers; food or beverage products; bitter compounds; sweeteners; bitterants; sour flavorants; salty flavorants; umami flavorants; plant or animal products; compounds known to be used in pet care products; compounds known to be used in personal care products; compounds known to be used in home products; pharmaceutical preparations; topical preparations; cannabis-derived or cannabis-related products; compounds known to be used in oral care products; beverages; scents, perfumes, or odorants; compounds known to be used in consumer products; silicone compounds; abrasives; surfactants; warming agents; smoking articles; fats, oils, or emulsions; and/or probiotic bacteria or supplements.

METHOD FOR PRODUCING NOVEL ORGANOMETALLIC COMPLEX AND AMINE COMPOUND

The purpose of the invention is to provide a novel organometallic compound that can be utilized as a catalyst having high generality, high activity, and excellent functional group selectivity. The invention pertains to a novel organometallic compound represented by general formula (1) that catalyzes a reductive amination reaction.

Memory of chirality (MOC) concept in imino-aldol reaction: Enantioselective synthesis of α,β-diamino esters and aziridines

A simple strategy for the synthesis of chiral α,β-diamino- and α-amino,β-hydroxy ester derivatives in high yields with moderate to high ee has been developed via asymmetric imino-aldol and aldol reactions, respectively, starting from protected aminoesters employing memory of chirality concept for chiral induction. This strategy has been extended for the enantioselective synthesis of aziridines (ee up to 92%). The absolute configuration of the imino-aldol adducts has been determined. The stereochemical outcome of the products has been explained by a suitable mechanism and supported by computational studies.

CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER

[Object] It is to provide a novel LXRβ agonist useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate: (wherein, each V and W independently show N or C—R7; each X and Y independently show CH2, C═O, SO2, etc; Z shows CH or N; each R1, R2 and R7 independently show a hydrogen atom, C1-8 alkyl group, etc.; R3 shows C1-8 alkyl group; R4 shows an optionally substituted C6-10 aryl group or an optionally substituted 5- to 11-membered heterocyclic group; R5 and R6 show a hydrogen atom, etc.; L shows a C1-8 alkyl chain optionally substituted with an oxo group, etc.; and n shows any integer of 0 to 2.)